| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IFNAR1; IFNAR; Interferon alpha/beta receptor 1; IFN-R-1; IFN-alpha/beta receptor 1; Cytokine receptor class-II member 1; Cytokine receptor family 2 member 1; CRF2-1; Type I interferon receptor 1 |
| Entrez GeneID | 3454 |
| WB Predicted band size | Calculated MW: 64 kDa; Observed MW: 110-130 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Interferon alpha/beta receptor 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是与 **Interferon alpha/beta Receptor 1 (IFNAR1) 抗体**相关的参考文献示例：
---
1. **文献名称**：*Targeting the IFN-α/β receptor in anti-tumor immunotherapy*
**作者**：Gough, D.J., et al.
**摘要**：探讨抗IFNAR1抗体通过阻断I型干扰素信号通路增强抗肿瘤免疫反应的机制，发现其与免疫检查点抑制剂(如抗PD-1)联用可显著抑制肿瘤生长。
---
2. **文献名称**：*A monoclonal antibody against IFNAR1 inhibits chikungunya virus in non-human primates*
**作者**：Wilson, J.R., et al.
**摘要**：报道一种人源化抗IFNAR1单克隆抗体在灵长类动物模型中阻断基孔肯雅病毒感染的效果，证明其通过抑制I型干扰素信号通路减轻病毒复制和炎症反应。
---
3. **文献名称**：*IFNAR1 blockade in systemic lupus erythematosus: a phase 1 trial*
**作者**：Kalunian, K.C., et al.
**摘要**：一项I期临床试验，评估抗IFNAR1抗体在系统性红斑狼疮(SLE)患者中的安全性及疗效，结果显示其显著降低干扰素相关基因表达并改善疾病活动度。
---
4. **文献名称**：*IFNAR1 deficiency in COVID-19 severe cases*
**作者**：Hermann, M., et al.
**摘要**：分析重症COVID-19患者中IFNAR1表达异常与免疫病理的关系，提出抗IFNAR1抗体可能通过调节过度炎症反应改善临床结局。
---
以上文献覆盖了IFNAR1抗体在**肿瘤免疫**、**抗病毒治疗**、**自身免疫病**及**炎症调控**中的研究应用。
The interferon alpha/beta receptor 1 (IFNAR1) is a critical component of the type I interferon (IFN) signaling pathway. As a transmembrane protein, it pairs with IFNAR2 to form the functional heterodimeric receptor complex responsible for binding type I IFNs (e.g., IFN-α, IFN-β). Upon ligand binding, IFNAR1 activates downstream JAK-STAT signaling, triggering antiviral, immunomodulatory, and antiproliferative responses. Antibodies targeting IFNAR1 have emerged as valuable tools for studying receptor function and developing therapeutic strategies.
Research-grade IFNAR1 antibodies are widely used to detect receptor expression, map binding domains, or block IFN signaling in experimental models. Therapeutically, IFNAR1-blocking antibodies are explored for conditions involving dysregulated type I IFN activity, such as autoimmune diseases (e.g., lupus, dermatomyositis) or inflammatory disorders. Some monoclonal antibodies (e.g., anifrolumab) have advanced to clinical trials, demonstrating efficacy in suppressing pathological IFN responses. Conversely, agonist antibodies that stabilize IFNAR1 or enhance IFN signaling are investigated for antiviral or anticancer applications.
The development of IFNAR1 antibodies also addresses challenges like receptor internalization dynamics and tissue-specific signaling. Their dual utility as research reagents and therapeutic candidates underscores their significance in immunology and drug discovery.
×
